The use of weight-loss jabs may be associated with wider health benefits including lower risk of stroke and dementia, a study ...

The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar Equity Research. Current market leaders include Novo Nordisk NVO and Eli Lilly LLY with ...

There's new evidence the class of drugs that includes Ozempic may have health benefits that go beyond diabetes treatment and weight loss. A major new study suggests these drugs could help with dozens ...

One of the world’s largest studies of Ozempic, Mounjaro and other blockbuster diabetes and obesity drugs highlighted their ...

Researchers have found links to multiple new benefits – and new side effects – in a study of weight-loss drugs such as ...

Recent research reveals that weight-loss injections reduce the risk of 42 health conditions in people with diabetes, ...

A major new study has highlighted significant health risks associated with popular weight loss injections such as Ozempic, ...

A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including dementia and cardiovascular diseases, although experts warned against seeing ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat substance abuse disorders, psychosis, infections, cancer, and dementia.

Ozempic and Wegovy are increasingly available in Australia and worldwide to treat type 2 diabetes and obesity.Authors Lauren Ball Professor of ...

The largest analysis to date of patients taking GLP-1 receptor agonists (GLP-1RAs) has investigated their effects on nearly 175 diseases, and found that compared to three other classes of diabetes ...